Clinical Trial Update: Adjuvant CDK4/6 Inhibitor Use in HR+/HER2- Breast Cancer

View source ↗

Summary

A clinical trial update announcing recruitment for a study evaluating adjuvant CDK4/6 inhibitors in hormone receptor-positive, HER2-negative breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Snippet

Sponsor: Wenjin Yin | Conditions: Breast Cancer | Status: RECRUITING